Published in Oncotarget on May 17, 2016
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers (Basel) (2017) 0.75
The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer. PLoS One (2017) 0.75
Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget (2017) 0.75
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 6.91
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol (1990) 4.05
Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 3.27
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One (2010) 2.32
Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res (1997) 2.30
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res (2004) 1.80
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med (2012) 1.69
Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J (1992) 1.68
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J (2005) 1.51
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res (2002) 1.44
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood (1998) 1.35
Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res (2005) 1.27
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest (2004) 1.25
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J (2010) 1.20
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene (2011) 1.18
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene (1999) 1.14
DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics (2004) 1.12
Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res (1998) 1.11
Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer (2009) 1.11
Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res (1995) 1.07
In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol (2005) 1.06
Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem (2000) 1.06
Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res (2000) 1.05
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res (2014) 1.02
Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol (2005) 0.99
Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer (2014) 0.97
Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics (2012) 0.96
Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers (Basel) (2014) 0.94
VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Mol Cell (2013) 0.94
Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity. Am J Pathol (2011) 0.93
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int J Oncol (2009) 0.90
HGF-induced DU145 cell scatter assay. Methods Mol Biol (2011) 0.90
Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer (1998) 0.90
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia (2001) 0.90
Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res (2013) 0.89
Targeting the oncogenic Met receptor by antibodies and gene therapy. Oncogene (2014) 0.87
Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology (2014) 0.84
Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer (2001) 0.83
Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci (2014) 0.83
Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Cancer Sci (2013) 0.81
MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer Res (2014) 0.80
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. ACS Med Chem Lett (2014) 0.79
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer Res (2014) 0.78
The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies. Bioorg Med Chem Lett (1998) 0.78
The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand. Bioorg Med Chem Lett (2000) 0.78
K-Ras, intestinal homeostasis and colon cancer. Curr Clin Pharmacol (2015) 0.78
Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Med Chem Lett (2015) 0.76
α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer. ChemMedChem (2016) 0.76